Drug
Pertuzumab clinical trials
Also written Perjeta, rhuMAb 2C4, RO4368451 and Poherdy.
- studies test it
- 157
- open now
- 37
- in phase 3
- 30
- first study started
- 2001
Keep track of what changes. Save the pertuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Biosimilars in development
- BCD-178
- 4
- HS627
- 3
- HLX11
- 3
- EG1206A
- 3
- TQB2440
- 2
Studies by the year they started
157 studies that test it; most in 2015 (13)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 5 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 12 |
| 2014 | 8 |
| 2015 | 13 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 2 |
| 2020 | 13 |
| 2021 | 11 |
| 2022 | 11 |
| 2023 | 12 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 32
- Phase 2
- 99
- Phase 3
- 30
- Phase 4
- 3
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 58 · Other 99
Hoffmann-La Roche (28) · Genentech, Inc. (11) · Dana-Farber Cancer Institute (6) · National Cancer Institute (NCI) (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Fudan University (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · MedSIR (2)
Often tested with
Tested in the same studies.
Trastuzumab (98) · Paclitaxel (28) · Ado-Trastuzumab Emtansine (17) · Docetaxel (14) · Atezolizumab (13) · Albumin-Bound Paclitaxel (12) · Carboplatin (10) · Erlotinib (10)
Studies
Open first, then newest update. How each study uses pertuzumab is read from its arms, and is right about nine times in ten.
Testing it · 157
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07857226Written as Pertuzumab
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Pertuzumab
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingPhase 2Shengjing HospitalNCT07795424Written as Pertuzumab (TQB2440)
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingPhase 2University of Illinois at ChicagoNCT06441890Written as Pertuzumab
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingPhase 2Polly A. Niravath, MDNCT07772245Written as Pertuzumab
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as Pertuzumab
- Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingPhase 1/2Liu ShuNCT07739511Written as Paclitaxel oral solution plus Trastuzumab and Pertuzumab
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Pertuzumab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as T-DM1 and Pertuzumab
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingPhase 2National Taiwan University HospitalNCT07565324Written as Pertuzumab
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07095023Written as Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
- Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingPhase 2Rutgers, The State University of New JerseyNCT07402473Written as Pertuzumab
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as HER2, pyrotinib + pertuzumab/trastuzumab
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Trastuzumab plus Pertuzumab
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05325632Written as Pertuzumab
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingPhase 3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07377643Written as Pertuzumab
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134Written as Pertuzumab Injection
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07393425Written as Pertuzumab
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07340398Written as Pertuzumab
See all 157 studies that test pertuzumab →
Given in every arm · 86 — pertuzumab is usual care beside what is tested
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Written as Pertuzumab
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754Written as Pertuzumab
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingPhase 3SWOG Cancer Research NetworkNCT07578116Written as Pertuzumab
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06876714Written as Pertuzumab
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingPhase 2M.D. Anderson Cancer CenterNCT07407920Written as Pertuzumab
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269Written as Pertuzumab
- Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingPhase 3Shanghai Jiao Tong University School of MedicineNCT07797218Written as Pertuzumab
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05150691Written as Pertuzumab Injection
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT06891833Written as Pertuzumab
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07716046Written as Pertuzumab
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07518173Written as Pertuzumab
- Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07616427Written as Trastuzumab + Pertuzumab
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07610720Written as Pertuzumab
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingPhase 1/2NYU Langone HealthNCT07612215Written as Pertuzumab
- Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerRecruitingPhase 2University of WashingtonNCT04329065Written as Pertuzumab
- Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerRecruitingPhase 2University of Kansas Medical CenterNCT07220135Written as Pertuzumab (or biosimilar)
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07527806Written as Pertuzumab
- Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.Not yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07528898Written as Pertuzumab
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT07371585Written as Pertuzumab
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07335081Written as pertuzumab
Showing 20 of 86.
As the comparator · 32 — what is tested is compared with pertuzumab
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruitingPhase 1Shanghai Henlius BiotechNCT07776132Written as HLX11
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingPhase 2Fudan UniversityNCT07856303Written as Pertuzumab
- A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07140393Written as Trastuzumab+ Pertuzumab
- A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT07545044Written as Pertuzumab
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460Written as Pertuzumab
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07043725Written as Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07294508Written as T-Dxd + Pertuzumab
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05760612Written as Trastuzumab and Pertuzumab
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Written as Pertuzumab
- Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingPhase 2Henan Cancer HospitalNCT07136974Written as Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingPhase 3Shanghai JMT-Bio Inc.NCT05838066Written as Pertuzumab
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06278870Written as Pertuzumab
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingPhase 2Shengjing HospitalNCT05638594Written as Pertuzumab
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingPhase 2Fujian Medical University Union HospitalNCT05292742Written as Trastuzumab+Pertuzumab/Trastuzumab
- TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Not yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04760431Written as Pertuzumab
- Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT04900311Written as pertuzumab + trastuzumab + nab-paclitaxel
- A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07196774Written as Pertuzumab Injection
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingPhase 3Shanghai JMT-Bio Inc.NCT06747338Written as Pertuzumab
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05319873Written as Pertuzumab
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerTerminatedPhase 3Biocon Biologics UK LtdNCT06038539Written as Perjeta plus trastuzumab, carboplatin and docetaxel
Showing 20 of 32.
Codes
What other systems call pertuzumab · ClinicalTrials.gg INT004642
- MeSH (NLM) C485206pertuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K16AIQ8CTMPERTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1298944Confirmed FDA, Wikidata
- Wikidata Q1998021pertuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38692PertuzumabOne source FDA
- DrugBank DB06366One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C485206 | pertuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K16AIQ8CTM | PERTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1298944 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1998021 | pertuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38692 | Pertuzumab | One source FDA |
| DrugBank | DB06366 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.